<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Flach, H.Z.</title>
    <link>http://repub.eur.nl/res/aut/6496/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>New ischaemic brain lesions on MRI after stenting or endarterectomy for symptomatic carotid stenosis: a substudy of the International Carotid Stenting Study (ICSS) (Article)</title>
      <link>http://repub.eur.nl/res/pub/18612/</link>
      <pubDate>2010-04-01T00:00:00Z</pubDate>
      <description>Background: The International Carotid Stenting Study (ICSS) of stenting and endarterectomy for symptomatic carotid stenosis found a higher incidence of stroke within 30 days of stenting compared with endarterectomy. We aimed to compare the rate of ischaemic brain injury detectable on MRI between the two groups. Methods: Patients with recently symptomatic carotid artery stenosis enrolled in ICSS were randomly assigned in a 1:1 ratio to receive carotid artery stenting or endarterectomy. Of 50 centres in ICSS, seven took part in the MRI substudy. The protocol specified that MRI was done 1-7 days before treatment, 1-3 days after treatment (post-treatment scan), and 27-33 days after treatment. Scans were analysed by two or three investigators who were masked to treatment. The primary endpoint was the presence of at least one new ischaemic brain lesion on diffusion-weighted imaging (DWI) on the post-treatment scan. Analysis was per protocol. This is a substudy of a registered trial, ISRCTN 25337470. Findings: 231 patients (124 in the stenting group and 107 in the endarterectomy group) had MRI before and after treatment. 62 (50%) of 124 patients in the stenting group and 18 (17%) of 107 patients in the endarterectomy group had at least one new DWI lesion detected on post-treatment scans done a median of 1 day after treatment (adjusted odds ratio [OR] 5·21, 95% CI 2·78-9·79; p&lt;0·0001). At 1 month, there were changes on fluid-attenuated inversion recovery sequences in 28 (33%) of 86 patients in the stenting group and six (8%) of 75 in the endarterectomy group (adjusted OR 5·93, 95% CI 2·25-15·62; p=0·0003). In patients treated at a centre with a policy of using cerebral protection devices, 37 (73%) of 51 in the stenting group and eight (17%) of 46 in the endarterectomy group had at least one new DWI lesion on post-treatment scans (adjusted OR 12·20, 95% CI 4·53-32·84), whereas in those treated at a centre with a policy of unprotected stenting, 25 (34%) of 73 patients in the stenting group and ten (16%) of 61 in the endarterectomy group had new lesions on DWI (adjusted OR 2·70, 1·16-6·24; interaction p=0·019). Interpretation: About three times more patients in the stenting group than in the endarterectomy group had new ischaemic lesions on DWI on post-treatment scans. The difference in clinical stroke risk in ICSS is therefore unlikely to have been caused by ascertainment bias. Protection devices did not seem to be effective in preventing cerebral ischaemia during stenting. DWI might serve as a surrogate outcome measure in future trials of carotid interventions. Funding: UK Medical Research Council, the Stroke Association, Sanofi-Synthélabo, European Union, Netherlands Heart Foundation, and Mach-Gaensslen Foundation.</description>
    </item> <item>
      <title>Assessment of feasibility of endovascular treatment of ruptured intracranial aneurysms with 16-detector row CT angiography (Article)</title>
      <link>http://repub.eur.nl/res/pub/14755/</link>
      <pubDate>2008-11-01T00:00:00Z</pubDate>
      <description>Background: It is unclear whether 16-detector row CT angiography (CTA) can replace digital subtraction angiography (DSA) to assess the feasibility of endovascular treatment (EVT) in the acute phase after aneurysmal subarachnoid hemorrhage. Methods: We studied 80 consecutive patients with aneurysmal subarachnoid hemorrhage, who underwent both CTA and DSA. Two interventional neuroradiologists independently scored CTA and, immediately thereafter, DSA with respect to feasibility of EVT. We determined whether CTA without DSA was sufficient for a definite judgment. We also assessed interobserver agreement. Results: The 2 readers judged EVT to be feasible in 24 and 37 patients with CTA alone and not feasible in 34 and 20 patients. In these patients, DSA yielded additional information in 6 (reader 1) and 5 patients (reader 2), which did not affect treatment decision. In 19 and 7 patients, DSA was considered inferior to CTA. In the remaining patients (n = 22 and 23, respectively), feasibility of EVT could not be judged with CTA alone, and DSA results were required in addition for a treatment decision. Interobserver agreement on feasibility of EVT was just fair (κ &lt;0.40). Conclusions: In our series of patients, 16-detector row CTA was a reliable investigation to assess feasibility of EVT of ruptured intracranial aneurysms in most patients. Further, we found that interobserver disagreement on feasibility of EVT was considerable.</description>
    </item> <item>
      <title>Epstein-Barr virus and disease activity in multiple sclerosis (Article)</title>
      <link>http://repub.eur.nl/res/pub/8433/</link>
      <pubDate>2005-01-01T00:00:00Z</pubDate>
      <description>OBJECTIVES: To study in relapsing-remitting (RR) multiple sclerosis (MS) whether exacerbations and brain activity as measured by magnetic resonance imaging (MRI) are associated with plasma levels of anti-Epstein Barr (EBV) antibodies and EBV DNA. METHODS: This was a prospective study with 73 RR MS patients followed for an average of 1.7 years with frequent neurological examination and blood sampling. Antibodies to various EBV proteins were measured by ELISA and plasma EBV DNA was measured by PCR. RESULTS: All MS patients had IgG antibodies to EBV (viral capsid antigen (VCA) and/or EBV nuclear antigen (EBNA)), irrespective whether samples were taken at stable disease or exacerbation. A significantly elevated percentage of the patients (48%) had antibodies against EBV antigens (early antigen, EA) that indicate active viral replication, compared with the age matched healthy controls (25%). Antibodies against a control herpesvirus, cytomegalovirus, were similar between the two groups. The percentage of EA positive individuals and EA titres did not differ between stable disease or exacerbation. Anti-VCA IgM was positive in three cases, unrelated to disease activity. Using a highly sensitive PCR on 51 samples taken at exacerbation visits, only three patients were found to have one timepoint with viraemia, and this viraemia was unrelated to disease activity. Of special note was the fact that anti-EA seropositive patients remained seropositive during follow up, with stable titres over time. We hypothesised that these patients may constitute a subgroup with higher disease activity, due to the triggering effect of a chronic attempt of the virus to reactivate. The EA positive group did not differ from the EA negative with respect to clinical disease activity or other characteristics. However, in the EA positive group, analysis with gadolinium enhanced MRI indicated more MRI disease activity. CONCLUSIONS: There was no evidence for increased clinical disease activity in the subgroup of MS patients with serological signs of EBV reactivation. However, the observation that chronic EBV reactivation may be associated with increased inflammatory activity as assessed by gadolinium enhanced MRI lesions should be reproduced in a larger and independent dataset.</description>
    </item> <item>
      <title>Prospective study on the relationship between infections and multiple sclerosis exacerbations (Article)</title>
      <link>http://repub.eur.nl/res/pub/9887/</link>
      <pubDate>2002-01-01T00:00:00Z</pubDate>
      <description>One of the characteristics of multiple sclerosis is the unpredictable
      occurrence of exacerbations and remissions. These fluctuations in disease
      activity are related to alterations in (auto-)immune activity.
      Exacerbations lead to short-term morbidity, but may also influence
      long-term disability. This longitudinal study in 73 patients with
      relapsing-remitting multiple sclerosis assessed the contribution of
      systemic infections to the natural course of exacerbations. In addition,
      we analysed whether infections lead to an increase in the number of
      gadolinium-enhancing lesions. A total of 167 infections and 145
      exacerbations were observed during 6466 patient weeks. During a predefined
      at-risk period (ARP) of 2 weeks before until 5 weeks after the onset of a
      clinical infection (predominantly upper airway infections), there was an
      increased risk of exacerbations (rate ratio 2.1), which is in accordance
      with previous studies. Exacerbations with onset during the ARP led more
      frequently to sustained deficit [increase of &gt; or =1 Expanded Disability
      Status Scale (EDSS) point or &gt; or =0.5 above EDSS 5.5 for &gt;3 months] than
      exacerbations with onset outside the ARP, with a rate ratio of 3.8. Minor
      and major exacerbations were equally distributed between the ARP and
      non-ARP onset groups. ARP exacerbations were associated with significantly
      higher plasma levels of the inflammatory marker soluble intracellular
      adhesion molecule 1 than non-ARP exacerbations, indicating relatively
      enhanced immune activation during ARP relapses. Three serial MRI scans
      were performed after the onset of an infection over a 6-week period. There
      was no difference in the number of gadolinium-enhancing lesions between
      the three time points. In conclusion, exacerbations in the context of a
      systemic infection lead to more sustained damage than other exacerbations.
      There is no indication that this effect occurs through enhanced opening of
      the blood-brain barrier.</description>
    </item> <item>
      <title>Best cases from the AFIP. Maffucci syndrome: radiologic and pathologic findings. Armed Forces Institutes of Pathology (Article)</title>
      <link>http://repub.eur.nl/res/pub/9759/</link>
      <pubDate>2001-01-01T00:00:00Z</pubDate>
      <description></description>
    </item>
  </channel>
</rss>